Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease: The Task Force on ACE-inhibitors of the European Society of Cardiology

European Heart Journal

Volumn 25, Issue 16, 2004, Pages 1454-1470

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTACID AGENT; BENAZEPRIL; CAPTOPRIL; CARBOXYL GROUP; CILAZAPRIL; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; LISINOPRIL; NONSTEROID ANTIINFLAMMATORY AGENT; PERINDOPRIL; PHOSPHINE DERIVATIVE; QUINAPRIL; RAMIPRIL; SPIRAPRIL; THIOL DERIVATIVE; TRANDOLAPRIL; ZOFENOPRIL;

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ANGIONEUROTIC EDEMA; ANURIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONFERENCE PAPER; CONSENSUS; COUGHING; DISEASE CLASSIFICATION; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG CLASSIFICATION; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; EUROPE; FETUS DISEASE; FIBRINOLYSIS; HEART DEATH; HEART DISEASE; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE CONTRACTION; HIGH RISK POPULATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INTRAUTERINE GROWTH RETARDATION; KIDNEY DYSFUNCTION; KIDNEY DYSPLASIA; KIDNEY FUNCTION; LUNG HYPOPLASIA; MITOSIS INHIBITION; NEUROENDOCRINE SYSTEM; NEWBORN DEATH; NEWBORN DISEASE; OLIGOHYDRAMNIOS; PRIORITY JOURNAL; PROTEINURIA; SECONDARY PREVENTION; SIDE EFFECT; TERATOGENESIS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; DEATH, SUDDEN, CARDIAC; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART DISEASES; HUMANS; HYPERTENSION;

EID: 4143126680     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2004.06.003     Document Type: Conference Paper

References (113)

1. Williams G.H. Converting-enzyme inhibitors in the treatment of hypertension. N. Engl. J. Med. 319:1988;1517-1525
2. Kostis J.B. Angiotensin-converting enzyme inhibitors. Emerging differences and new compounds. Am. J. Hypertens. 2:1989;57-64
3. Brown N.J., Vaughan D.E. Angiotensin-converting enzyme inhibitors. Circulation. 97:1998;1411-1420
4. Jackson EK. Renin and angiotensin. In: Hardman JG, Limbird LE, Editors. The pharmacological basis of therapeutics. 10th Ed. New York; 2001:pp. 809-841
5. Hoyer J., Schulte K.L., Lenz T. Clinical pharmacokinetics of angiotensin converting enzyme (AC) inhibitors in renal failure. Clin. Pharmacokinet. 24:1993;230-254
6. Lonn E.M., Yusuf S., Jha P., et al. Emerging role of angiotensin- converting enzyme inhibitors in cardiac and vascular protection. Circulation. 90:1994;2056-2069
7. Zimmerman B.G., Sybertz E.J., et al. Interaction between sympathetic and renin-angiotensin system. J. Hypertens. 2:1984;581-592
8. Hornig H., Kohler C., Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation. 95:1997;1115-1118
9. Linz W., Wohlfart P., Schoelkens B.A., et al. Interactions among ACE, kinins and NO. Cardiovasc. Res. 43:1999;549-561
10. Dzau V.A. The relevance of tissue angiotensin-converting-enzyme: manifestations in mechanistic and endpoint data. Am. J. Cardiol. 88:2001;1-20
11. Giannettasio C., Grassi G., Seravalle G., et al. Investigation of reflexes from volume and baroreceptors during converting-enzyme inhibition in humans. Am. Heart J. 117:1989;740-745
12. Schmieder R.E., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: A meta-analysis of randomized double-blind studies. JAMA. 275:1996;1507-1513
13. Thadei S., Virdis A., Ghiadoni L., et al. Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilation in patients with essential hypertension. J. Hypertens. 16:1998;447-456
14. Hornig B., Landmesser U., Kohler C., et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation. 103:2001;799-805
15. Hornig B., Arakawa N., Drexler H. Effect of ACE inhibition on endothelial dysfunction in patients with chronic heart failure. Eur. Heart J. 19(Suppl G):1998;G48-G53
16. Francis GS, Benedict C, Johnstone DE et al. for the SOLVD Investigators. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 1990;82:1724-9
17. Swedberg K, Eneroth P, Kjekshus J et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990;82:1730-6
18. Swedberg K. Importance of neuroendocrine activation in chronic heart failure. Impact on treatment strategies. Eur. J. Heart Fail. 2:2000;229-233
19. Husain A. The chymase-angiotensin system in humans. J. Hyperten. 11:1993;1155-1159
20. Lee A.F., MacFadyen R.J., Struthers A.D. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur. J. Heart Fail. 1:1999;401-406
21. Boon W.C., McDougall J.G., Coghlan J.P. Hypothesis: aldosterone is synthesized by an alternative pathway during severe sodium depletion. 'A new wine in an old bottle'. Clin. Exp. Pharmacol. Physiol. 25:1998;369-378
22. + stimulated aldosterone secretion. Mol. Cell Endocrinol. 175:2001;157-171
23. Paul M., Ganten D. The molecular basis of cardiovascular hypertrophy: the role of the renin-angiotensin system. J. Cardiovasc. Pharmacol. 19(Suppl. 5):1992;S51-S58
24. Schiffrin E., Deng L. Comparison of effects of angiotensin I-converting enzyme inhibition and β-blockade for 2 years on function of small arteries from hypertensive patients. Hypertension. 25:1995;699-703
25. Matsuda H., Hayashi K., Arakawa K. Zonal heterogeneity in action of angiotensin-converting enzyme inhibitor on renal microcirculation: role of intrarenal bradykinin. J. Am. Soc. Nephrol. 10:1999;2272-2282
26. Keane W.F., Shapiro B.E. Renal protective effects of angiotensin- converting enzyme inhibition. Am. J. Cardiol. 65:1990;49I-453
27. Ruggenenti P., Perna A., Gherardi G., et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies and non-nephrotic proteinuria. Lancet. 354:1999;359-364
28. Lewis E.J., Hunsicker L.G., Bain R.P., et al. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 329:1993;1456-1462
29. Pitt B. Potential role of angiotensin converting enzyme inhibitors in the treatment of atherosclerosis. Eur. Heart J. 16:1995;49-54
30. Schoelkens B.A., Landgraf W. ACE inhibition and atherosclerosis. Can. J. Physiol. Phatmacol. 80:2002;354-359
31. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77
32. Yusuf S., Pepine C.J., Garces C., et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fraction. Lancet. 340:1993;1173-1178
33. Teo KK, Yusuf S, Pfeffer M et al. for the ACE Inhibitors Collaborative Group. Effects of long-term treatment with angiotensin-converting enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002;360:1037-43
34. The Heart Outcomes Prevention Evaluation Study Investigators (HOPE). Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53
35. Lonn E.M., Yusuf S., Dzavik V., et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 103:2001;919-925
36. Vaughan D. The renin-angiotensin system and fibrinolysis. Am. J. Cardiol. 79(Suppl. 5):1997;12-16
37. DiBianco R. Adverse reactions with angiotensin converting enzyme inhibitors. Med. Toxicol. 1:1986;122-141
38. Visser L.E., Stricker B.H., van der Velden J., et al. Angiotensin converting enzyme inhibitor associated cough: a population-based case-control study. J. Clin. Epidemiol. 48:1995;851-857
39. Wood R. Bronchospasm and cough as adverse reactions to the ACE inhibitors captopril, enalapril and lisinopril. A controlled retrospective cohort study. Br. J. Clin. Pharmacol. 39:1995;265-270
40. Charlon V., Dollow S., Fidel J., et al. Reproducibility of angiotensin converting enzyme inhibitor induced cough: a double-blind randomised study. Br. J. Clin. Pharmacol. 39:1995;125-129
41. Israili Z.H., Hall W.D. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann. Intern. Med. 117:1992;234-242
42. Ahuja T.S., Freeman D., Mahnken J.D., et al. Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. Am. J. Nephrol. 20:2000;268-272
43. The RALES investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure. (The randomized aldactone evaluation study: RALES). Am J Cardiol 1996;78:902-7
44. Wynckel A., Ebikili B., Melin J.-.P., et al. Long-term follow-up of acute renal failure caused by angiotensin converting enzyme inhibitors. Am. J. Hypertens. 11:1998;1080-1086
45. Brown N., Ray W., Snowden M., et al. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin. Pharmacol. Ther. 60:1996;8-13
46. Sedman A.B., Kershaw D.B., Bunchman T.E. Recognition and management of angiotensin converting enzyme inhibitors. Pediatr. Nephrol. 9:1995;382-385
47. Brent R.L., Beckman D.A. Angiotensin-converting enzyme inhibitors, an embryopathic class of drugs with unique properties: information for clinical theratology counselors. Teratology. 43:1991;543-546
48. Oakley C, Child A, Iung B, Prebitero P, Tornos P for the Task force on the management of cardiovascular diseases during pregnancy of the European Society of Cardiology. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 2003;24:761-81
49. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM et al. for the Task force on hypertrophic cardiomyopathy. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. Eur Heart J 2003;25:1965-91
50. Remme WJ, Swedberg K et al. for the task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60
51. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure) ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult 2002. Available from: http://www.acc.org
52. Shekelle P.G., Rich M.W., Morton S.C., et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. A meta-analysis of major clinical trials. J. Am. Coll. Cardiol. 41:2003;1529-1538
53. Flather M, Yusuf S, Køber L, Pfeffer M, Hall A, Murria G et al. for the ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000;355:1575-781
54. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-35
55. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302
56. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. 325:1991;303-310
57. Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy. Lancet 1993;342:821-8
58. Narang R., Swedberg K., Cleland J.G. What is the ideal study design for evaluation of treatment for heart failure? Insights from trials assessing the effect of ACE inhibitors on exercise capacity. Eur. Heart J. 17:1996;120-134
59. Northridge D.B., Rose E., Raftery E.D., et al. A multicentre, double-blind, placebo-controlled trial of quinapril in mild, chronic heart failure. Eur. Heart J. 14:1993;403-409
60. Gundersen T, Swedberg K, Amtorp O et al. Absence of effect on exercise capacity of 12-weeks treatment with ramipril in patients with moderate congestive heart failure. Ramipril Study Group. Eur Heart J 1994;15:1659-65
61. Gundersen T, Wiklund I, Swedberg K. Effects of 12 weeks of ramipril treatment on the quality of life in patients with moderate congestive heart failure: results of a placebo-controlled trial. Raipril Study Group. : Cardiovasc Drugs Ther (United States), Aug 1995;9:589-94
62. Packer M, Poole-Wilson PA, MD, Armstrong PW et al., on behalf of the ATLAS study group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312-8
63. The NETWORK investigators. Clinical outcome with enalapril in symptomatic chronic heart failure, a dose comparison. Eur Heart J 1998;19:481-9
64. MacMurray J., Cohen-Solal A., Dietz R., et al. Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. Eur. J. Heart Failure. 3:2001;495-502
65. Pitt B, A Poole-Wilson PA, Segl R, on behalf of the ELITE II investigators Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000:355:1582-7
66. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee for the OPTIMAAL Study Group Effects of losartan and captopril on mortality and morbidity high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360;752-60
67. Pfeffer MA, McMurray JJV, Velàsquez EJ et al. for the Valsartan in Acute Myocardial Infarction Trial Investigators Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. N Engl J Med 2003;349:1893-906
68. McMurray J.J.V., Östergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 362:2003;767-771
69. Packer M, Califf RM, Konstam MA for the OVERTURE Study Group. Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure, The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002;920:106-26
70. The SOLVD Investigators. Effect of enalapril on mortality and development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91
71. Jong P., Yusuf S., Rousseau M.F., et al. Effect of nealapril on 12 year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet. 361:2003;1843-1848
72. Vermes E., Ducharme A., Bourassa M.G., et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure. Insight from the studies of left ventricular dysfunction (SOLVD). Circulation. 107:2003;1291-1296
73. Kober L, Torp-Pedersen C, Carlsen JE et al. for the trandolapril cardiac evaluation (TRACE) study group: a clinical trial of the angiotensin converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;33:1670-76
74. Torp-Pedersen C, Kober L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 1999;354:9-12
75. Philbin E.F., Rocco T.A., Lindenmuth N.W., et al. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am. J. Med. 109:2000;605-613
76. Cleland J.G. ACE inhibitors for 'diastolic' heart failure? reasons not to jump to premature conclusions about the efficacy of ACE inhibitors among older patients with heart failure. Eur. J. Heart Fail. 3:2001;637-639
77. Effects of cardiac versus circulatory angiotensin-converting enzyme inhibition on left ventricular diastolic function and coronary blood flow in hypertrophic obstructive cardiomyopathy. Circulation 1998;97:1342-47
78. Devereux R.B., Palmieri V., Sharpe N., et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation. 104:2001;1248-1254
79. Beltman F., Heesen W., Smit A., et al. Two-year follow-up study to evaluate the reduction of left ventricular mass and diastolic function in mild to moderate diastolic hypertensive patients. J. Hypertens. Suppl. 16:1998;S15-S19
80. Yusuf S, Pfeffer MA, Swedberg K, Granger KB, Held P, McMurray JJV et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM Preserved Trial. Lancet 2003;362:777-781
81. Van de Werf et al. for the task force of the management of acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST segment elevation. Eur Heart J 2003;24:28-66
82. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction American College of Cardiology; September 1999. Available from: www.acc.org
83. Gottlieb S, MD, Leor J, Shotan A, Harpaz D, Boyko V, Rott D et al. Comparison of effectiveness of angiotensin-converting enzyme inhibitors after acute myocardial infarction in diabetic versus nondiabetic patients. Am J Cardiol 2003;92:1020-5
84. Swedberg K, Held P, Kjekshus J, y cols. Effects of early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSESSUS II). N Engl J Med 1992;327:678-84
85. Fourth International Study of Infarct Survival Collaborative Group. ISIS-IV: a randomised factorial trial assessing early oral captopril. Oral mononitrate and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85
86. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6 week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22
87. Chinese Cardiac Study Collaborative group. Oral captopril versus placebo among 13634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study. Lancet 1995;345:686-7
88. Ambrosioni E, Borghi C, Magnani B for the survival of myocardial infarction long term evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5
89. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100 000 patients in randomized trials. Circulation 1998;97:2202-12
90. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8
91. Wood D, De Backer G, Faergeman O, Graham I, Mancia G and Pyörälä K et al. for the Second Joint Task Force of European and other Societies†on Coronary Prevention: European Society of Cardiology, European Atherosclerosis Society, European Society of Hypertension, International Society of Behavioural Medicine, European Society of General Practice/Family Medicine, European Network. Prevention of coronary heart disease in clinical practice. Eur Heart J 1998;19:1434-503
92. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 2003;289:2560-72
93. De Backer G., Ambrosioni E., Borch-Johnses K., et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 24:2003;1601-1610
94. Hansson L., Lindholm L., Ekbom T., et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 354:1999;1751-1756
95. Estacio R., Jeffers B., Hiatt W., et al. The effect of nisoldipine as compared with enalapril on outcomes in patients with non-insulin dependant diabetes and hypertension. N. Engl. J. Med. 338:1998;645-652
96. Hansson L., Lindholm L., Niskanen L., et al. Effect of angiotensin converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 353:1999;611-616
97. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998;317:713-20
98. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998;317:703-13
99. Collaborative Group Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41
100. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other bloodpressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;355:1955-64
101. Staessen J.A., Wang J.G., Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 358:2001;1305-1315
102. Wing L.M., Reid C.M., Ryan P., et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med. 348(7):2003;583-592
103. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA 2002;288:2981-97
104. MacMahon S., Sharpe N., Gamble G., et al. Randomised, placebo controlled trial of the angiotensin converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive vascular disease. J. Am. Coll. Cardiol. 36:2000;438-443
105. Cashin-Hemphill L., Holmvang G., Chan R., et al. Angiotensin converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. Am. J. Cardiol. 83:1999;43-47
106. Teo K., Burton J., Buller C., et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT). Circulation. 102:2000;1748-1754
107. Arnold JMO, Yusuf S, Young J et al. on behalf of the HOPE Investigators. Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 2003;107:1284-90
108. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9
109. Bosch J, Yusuf S, Pogue J et al. Use of ramipril in preventing stroke: double blind randomised trial. Br Med J 2002;324;699-702
110. Sleight P., Yusuf S., Pogue J., et al. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet. 358:2001;2130-2131
111. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002;89:18A-25A
112. Priori SG, Aliot E, Blomström-Lundqvist C et al. for the Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001;22:1374-450
113. Priori SG, Aliot E, Blomström-Lundqvist C et al. for the Task Force on Sudden Cardiac Death of the European Society of Cardiology. Update on the guidelines for sudden cardiac death of the European Society of Cardiology. Eur Heart J 2003;24:13-5